SWTX - SpringWorks Therapeutics, Inc.
收市後：
| 前收市價 | 27.38 |
| 開市 | 27.36 |
| 買盤 | 0.00 x 900 |
| 賣出價 | 0.00 x 900 |
| 今日波幅 | 26.54 - 27.83 |
| 52 週波幅 | 19.25 - 39.78 |
| 成交量 | |
| 平均成交量 | 697,353 |
| 市值 | 1.731B |
| Beta 值 (5 年，每月) | 0.58 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -4.77 |
| 業績公佈日 | 2023年8月02日 - 2023年8月07日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 55.80 |
BenzingaHC Wainwright Believes Ayala's Initial Cancer Data Is Encouraging
Ayala Pharmaceuticals Inc (NASDAQ: Ayala) reported data from Part A of its Phase 2 (RINGSIDE) trial evaluating AL102 in patients with desmoid tumors on Tuesday. At 16 weeks, one of 13 patients treated with AL102 demonstrated an unconfirmed partial response, which HC Wainwright believes signals encouraging initial activity. HC Wainwright reiterated the Buy rating on the stock with a price target of $18. The analyst says that Ayala's initial data is encouraging in the context of the clinical devel
BenzingaSpringWorks Therapeutics Shares Jump On HC Wainwright Bullish Pitch
HC Wainwright points out that investors are enthusiastic about SpringWorks Therapeutics Inc (NASDAQ: SWTX) nirogacestat clinical profile for desmoid tumors after the R&D day held last week. As per a survey of U.S. oncologists treating patients with desmoid tumors, roughly 80% and 87% of medical oncologists believe that nirogacestat compares favorably to Bayer AG's (OTC: BAYRY) Nexavar (sorafenib) and that they are willing to switch current patients to nirogacestat, respectively. The analysts for